Sonus to meet FDA on EchoGen

Article

Ultrasound contrast developer Sonus Pharmaceuticals has a meeting with the Food and Drug Administration scheduled for April 27 to discuss the company's regulatory filing for EchoGen. The meeting was called as part of the Bothell, WA, company's

Ultrasound contrast developer Sonus Pharmaceuticals has a meeting with the Food and Drug Administration scheduled for April 27 to discuss the company's regulatory filing for EchoGen. The meeting was called as part of the Bothell, WA, company's discussions with the FDA over EchoGen's new drug application. The FDA in February said it required additional information on the NDA before it could be approved (SCAN 3/18/98).

Sonus also announced that EchoGen's medical marketing application (MMA) was scheduled to be reviewed in late March by Europe's Committee for Proprietary Medicinal Products (CPMP), which makes recommendations to the European Medicines Evaluation Agency. EMEA approval would allow Sonus to market EchoGen in the 15 nations of the European Union.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.